ClinicalTrials.gg
RecruitingNCT06780202Updated Mar 9, 2026

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

A Phase 2 interventional study of medrol dosepak and HYDROcodone Oral Tablet in Foot Injuries and Disorders, Ankle Injuries and Disorders and Achilles Tendon Injury, sponsored by Emory University. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Emory University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
18 Years to 95 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Foot Injuries with a site in United States — 9 open to participants now, 10 under way, none of them phase 3. Foot Injuries · United States.

Planned enrollment
Largest of 21
180 · median 46
Started
2025
with 4 others
Phase 2
Only one
of the 27
Registered
22nd of 27
by date
Lead sponsor
1 of 27
Emory University

Among the 27 studies in Foot Injuries with a site in United States, this one has the largest planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is the only one in phase 2, and was the 22nd registered.

Foot Injuries

60 studies on the registry are indexed under Foot Injuries; 15 are open to participants now.

Browse Foot Injuries studies →

Open to participants now

9 of the 27 studies in Foot Injuries with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 11 Foot Injuries studies recruiting now, 7 (64%) set no upper age limit and 3 (27%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years to 95 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Foot Injuries with a site in United States, or all of them as a file.
02

Study summary

This clinical trial aims to determine the effects of a 6-day low-dose methylprednisolone course on pain, nausea, and total opioid consumption in patients undergoing foot and ankle surgeries.

The secondary objective of the study is to determine and monitor the effects of the course on complications following surgery and patient-reported outcomes

Read the detailed description

The opioid epidemic continues to create a lasting impact on society, leading researchers to focus on ways to decrease opioid prescription rates and subsequently, opioid consumption. Opioid-naïve patients undergoing minor to major surgeries have been shown statistically to be largely affected.1 This includes significant numbers resulting from forefoot surgery specifically with around 6.2% of the mentioned population being at risk for new persistent opioid use.

This has provoked researchers to seek a new route that decreases exposure to opioid use through proposals for multimodal pain regimes.

A recent addition to some of these proposed treatments has been a 6-day low-dose oral methylprednisolone taper beginning on the day of surgery. This has been tested with "terrible triad" elbow injuries, distal radius fractures, and total shoulder arthroplasties with promising results showing decreased consumption of the as-needed opioid prescription. Furthermore, the results of these studies show a significant decrease in pain and increased range of motion following surgery. This is likely due to the anti-inflammatory functioning of glucocorticoids, without inhibiting the healing process.

Based upon the findings stated above, the proposed research will attempt to apply this new pain regime to foot and ankle surgeries, specifically forefoot, ankle, and Achilles surgeries, to take another step towards bettering perioperative care with opioid-free treatment

03

Conditions studied

  • Foot Injuries and Disorders
  • Ankle Injuries and Disorders
  • Achilles Tendon Injury

Keywords

  • VAS scale: visual analog scale
  • Medrol Dosepak
04

Who can participate

Ages eligible
18 Years to 95 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

-Emory Orthopedic patients undergoing foot and ankle surgery

Exclusion criteria

Exclusion Criteria:

  • Concurrent or significant injuries to other bones or organs
  • Local infections
  • History of alcohol or medical abuse, including prior opioid abuse
  • Smoking
  • History of severe heart disease, renal failure, liver dysfunction, active peptic ulcer disease, diabetes, rheumatoid arthritis, neurological or psychiatric diseases that could influence pain perception
  • Pre-existing immune suppression
  • Those deemed possibly non-compliant by the study team and,
  • All vulnerable populations (those unable to give consent, juveniles, pregnant women, prisoners, cognitively impaired and non-English speaking).
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Medrol

    The group will be given Medrol Dosepak in a tapered, low-dose manner, orally once a day. Subjects will be sent home with a pain journal where they will record their pain and nausea 3 times daily starting the day of surgery and the following 7 days along with their daily hydrocodone consumption. These journals will be collected at their 2-week post-op appointment which is scheduled ± 1 week. In this appointment, subjects will also be evaluated for complications.

    Drug: medrol dosepak · Drug: HYDROcodone Oral Tablet

  • Active comparator
    Standard of Care

    Each subject will receive the standard pain regime of both surgeons. This includes a nerve block before surgery for pain prevention. While in surgery, the subject will receive 10 mg of dexamethasone intravenously. Post-surgery, each subject will be instructed to take vitamin C for nerve pain and vitamin D for bone healing. They will also be provided with a prescription of aspirin for deep vein thrombosis (DVT) prophylaxis, ondansetron (Zofran) for nausea, and Colace for constipation relief. Both groups will receive a prescription of 20 5 mg hydrocodone pills to be taken as needed for pain, 1 every 6 hours Subjects will be sent home with a pain journal where they will record their pain and nausea 3 times starting the day of surgery and the following 7 days along with their daily hydrocodone consumption. Journals will be collected at their 2-week post-op appointment which is scheduled ± 1 week. Subjects will also be evaluated for complications

    Drug: HYDROcodone Oral Tablet

Interventions

  • DrugMethylprednisoloneStudies of MethylprednisoloneMethylprednisolone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Methylprednisolone is a corticosteroid with anti-inflammatory properties and immune suppression. This study will utilize a 6-day Medrol Dosepak: a tapered low-dose corticosteroid course taken orally once a day. This includes 6 tablets on day 1 (24 mg), 5 tablets on day 2 (20 mg), 4 tablets on day 3 (16 mg), 3 tablets on day 4 (12 mg), 2 tablets on day 5 (8 mg) and 1 tablet on day 6 (4 mg).

    Also known as: Methylprednisolone

  • DrugHydrocodoneStudies of HydrocodoneHydrocodone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    This study will utilize a prescription of 20 pills of hydrocodone, 5mg each, to be taken as needed for pain, 1 every 6 hours.

06

What researchers measure

Primary outcomes

  1. Post operative Nausea

    The subjects will report nausea along the visual analog scale (VAS scale), which they will be educated on before surgery. A VAS for nausea is a straight line with one end labeled "no nausea" and the other end labeled "worst nausea imaginable". The patient marks a point on the line to indicate their nausea level. The distance from the "no nausea" end of the line is used to score the nausea intensity

    Time frame: Baseline (Day 0), 7 days post op

  2. Post operative pain

    The subject will measure pain along the visual analog scale (VAS scale), which they will be educated on before surgery. A VAS for pain is a straight line with one end labeled "no pain" and the other end labeled "worst pain imaginable". The patient marks a point on the line to indicate their pain level. The distance from the "no pain" end of the line is used to score the pain intensity

    Time frame: Baseline, 0.25 months, 1.5 months, 3 months, 6 months

  3. Post operative opioid consumption

    Total number of opioids consumed each day will be captured.

    Time frame: Baseline (Day 0), 7 days post op

Secondary outcomes

  1. Complications due to the Medrol Dosepak

    Complications will be monitored via radiographs and clinical analyses at post-operative appointments for impaired wound-healing and infection

    Time frame: 1.5 months, 3 months, 6 months

  2. Patient reported outcomes

    Patient-reported outcomes will be measured along the 12-item Short Form Health Survey which measures the impact of their current health on everyday life, the Patient-Reported Outcomes Measurement Information System (PROMIS) which measures physical, mental, and social health and the VAS scale, which measures pain at rest

    Time frame: Baseline (pre operative assessment), Post operation (6 months)

07

Study locations

2 of 2 sites recruiting
  • Emory Musculoskeletal Institute, Emory Orthopaedics & Spine Center
    Atlanta, Georgia 30329, United States
    Recruiting
    • Jason Bariteau, MD · Contactjason.bariteau@emory.edu · 404-778-3350
    • Jason Kadakia, MD · Principal investigator
    • Rishin Bariteau, MD · Principal investigator
  • Emory Sports Medicine Complex and Emory Orthopaedics and Spine Center
    Johns Creek, Georgia 30022, United States
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jun 2027, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2025
First posted
Jan 17, 2025
StartActual
Jan 27, 2025
Primary completionEst.
Jun 2027
CompletionEst.
Dec 2027
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06780202
Lead sponsor
Emory University
Responsible party
Jason Bariteau (Associate Professor, Emory University) — Principal investigator
First posted
Jan 17, 2025
Start date
Jan 27, 2025
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Mar 9, 2026

Study contacts

Jason Bariteau, MD
Contact
jason.bariteau@emory.edu
404-778-3350
Rishin Kadakia, MD
principal investigator · Emory University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methylprednisolone

Start the discussion